US Government May Take Equity Stake in OpenAI

The State as Shareholder: Washington Eyes an Equity Position in OpenAI

Daily Signal — June 7, 2026

TL;DR: The Trump administration is actively discussing taking a direct equity stake in OpenAI, potentially seeding a “Public Wealth Fund” that would distribute AI-derived proceeds to citizens — a departure from conventional US industrial policy with few modern precedents. Simultaneously, Sriram Krishnan, one of the primary architects of the administration’s AI strategy, is departing the White House at month’s end, creating a consequential leadership vacuum precisely as these novel ownership proposals are being debated. The two developments together mean US AI governance is entering a structurally uncertain phase.

Today’s Themes

• Whether a government equity stake in a private frontier AI company can be structured without creating implicit bailout expectations or distorting competitive incentives in the AI market.
• The tension between the Trump administration’s nominally market-oriented posture and its growing openness to direct state ownership of technology assets.
• Whether a “Public Wealth Fund” backed by AI equity is a workable mechanism for broad benefit-sharing — or a politically appealing idea that lacks implementable governance structures.
• Leadership continuity risk in US AI policy at the exact moment the administration is considering its most interventionist move to date.
• Bipartisan convergence — from different directions — on the idea that public ownership of AI companies is a legitimate policy instrument.

Top Stories

Trump Administration Explores Taking an Equity Stake in OpenAI

What happened: President Trump stated publicly that he has been speaking with AI executives about arrangements where “the American people can benefit from the success of AI,” with CNBC reporting — cited by TechCrunch — that the administration has discussed taking a direct equity stake in OpenAI. Some of that equity would potentially seed a “Public Wealth Fund” proposed by OpenAI, designed so that proceeds could be distributed directly to citizens. Bloomberg reporting indicates CEO Sam Altman has been discussing the concept of government stakes in major AI companies since early 2025.

Why it matters: This proposal matters most to AI investors, existing and prospective OpenAI shareholders, and allied governments — not because public benefit-sharing is inherently objectionable, but because any equity arrangement between the US government and a specific frontier AI company creates structural entanglements that are difficult to unwind. A government shareholder has an incentive to protect the value of its position, which can subtly distort regulatory decisions, procurement choices, and responses to competitive pressure from foreign labs. The prior Intel precedent — a 10% government stake in a struggling chipmaker — was framed as industrial rescue. An OpenAI stake framed as prosperity-sharing is a different political logic, but the governance risks are similar or greater given OpenAI’s centrality to US AI infrastructure and its ongoing structural transformation from nonprofit to for-profit entity.

• Trump publicly described deals where “pieces could be given to the American public, where the American public essentially becomes a partner with the companies.”
• The proposed “Public Wealth Fund” would be seeded with equity and designed to distribute proceeds broadly, regardless of citizens’ wealth or capital access.
• The US government previously took a 10% stake in Intel, cited in reporting as a precedent for equity positions in tech companies.
• Senator Bernie Sanders has separately proposed a one-time 50% tax on OpenAI, Anthropic, and xAI payable in stock — a structurally different mechanism converging on a similar outcome of expanded public ownership.
• Observers on social media have raised the concern that a government equity stake could lay groundwork for a future bailout of OpenAI if the company faces financial distress.

Source: techcrunch.com

Sriram Krishnan to Leave White House AI Advisor Role at End of June

What happened: Sriram Krishnan, former tech executive and venture capitalist serving as a senior White House AI advisor, announced he will leave his role at the end of June 2026. In a post on X, he credited the Trump administration’s leadership for keeping the US ahead in the AI race and said his next chapter will involve “building institutions” aimed at tackling major challenges for “America and its allies.” The Washington Post, cited by TechCrunch, reports he plans to start an outside institution intended to retain influence over Trump’s AI policy from beyond government.

Why it matters: Krishnan’s departure is poorly timed for the administration’s own ambitions: he leaves just as the White House is contemplating its most structurally complex intervention in the AI market to date — a government equity stake in OpenAI. Anyone advising on that arrangement needs deep familiarity with both the policy precedents and the specific dynamics of frontier AI development. An outside institution may preserve Krishnan’s informal influence, but it removes him from the internal deliberations where the equity-stake concept will be stress-tested against legal, regulatory, and foreign-policy constraints. The open question of who replaces him in a formal advisory capacity is not procedural — it will materially shape how, or whether, these proposals acquire implementable structure.

• Krishnan’s departure is confirmed for the end of June 2026.
• He described his service as “a big privilege” and credited Trump’s leadership with maintaining US AI leadership.
• He plans to found an outside institution aimed at retaining influence over US AI governance and strategy.
• No successor has been named publicly, per available reporting.

Source: techcrunch.com

Pfizer’s Once-Monthly Obesity Drug Berobenatide Shows Continued Promise

What happened: New detailed clinical data on Pfizer’s experimental once-monthly obesity drug berobenatide — also referred to as Metsera — have been reported by STAT+, going beyond earlier topline disclosures. The more granular dataset is described as indicating the drug “continues to show potential,” reinforcing earlier signs of efficacy and tolerability. Berobenatide is designed to require only monthly injections, in contrast to existing obesity therapies that typically require weekly dosing. Further clinical testing and regulatory review remain required before efficacy, safety, and commercial viability can be fully assessed; long-term outcome data are not yet available from the reported excerpt.

Why it matters: For pharmaceutical investors and healthcare payers, the monthly dosing interval is the detail that warrants attention: adherence to injectable therapies drops significantly with frequent administration, and a once-monthly formulation that maintains competitive efficacy could command meaningful market share even if its weight-loss magnitude does not exceed current GLP-1 leaders. Whether the detailed data support that commercial thesis — as opposed to merely confirming the drug is not failing — requires access to the full STAT+ dataset, which is paywalled.

• Berobenatide targets once-monthly dosing, versus the weekly injections required by dominant current obesity drugs.
• STAT+ describes the new detailed data as showing the drug “continues to show potential” beyond earlier topline figures.
• Long-term outcomes and full Phase 3 data are not yet available based on the available report.
• The drug is entering a competitive field where multiple pharmaceutical companies are racing to develop next-generation obesity therapies.

Source: statnews.com

Security Watch

• Concentration of government influence over core AI infrastructure: If the US takes an equity stake in OpenAI, the governance terms governing model access, data use, and national security applications become critical. No such safeguards have been publicly described, and the absence of that detail is itself a risk indicator for allied governments and competing AI developers.
• Implicit bailout expectations: A government equity position — regardless of how it is framed publicly — creates political pressure to protect the value of that position. If OpenAI encounters financial distress, the existence of a government stake changes the calculus around intervention in ways that have not been openly debated.
• Policy continuity risk from Krishnan’s exit: Leadership transitions in senior AI advisory roles introduce the risk that ongoing negotiations — including any equity-stake discussions — lose institutional memory or shift in direction without a clear public signal, reducing predictability for industry and allied partners alike.

What to Watch Next

• Whether the White House publicly names a replacement for Sriram Krishnan before the end of June — the identity and background of that person will signal whether the administration is moving toward harder regulatory intervention or sustaining a lighter-touch posture.
• Whether any formal term sheet, legislative vehicle, or executive order emerges to give the proposed OpenAI equity stake legal and governance structure — the gap between Trump’s public statements and an implementable arrangement is substantial.
• How OpenAI’s existing investors and its board respond publicly to the equity-stake discussions, given that government ownership would introduce a shareholder with interests potentially distinct from commercial return maximization.
• Whether Senator Sanders’s 50% stock-payable tax proposal gains legislative traction, and whether it intersects with or competes against the administration’s own equity-stake concept in any congressional debate.
• The release of full clinical data on berobenatide — specifically whether STAT+’s characterization of “continued potential” is supported by effect-size numbers that would justify a commercial challenge to existing GLP-1 therapies.

Bottom Line

The Trump administration’s simultaneous consideration of a government equity stake in OpenAI and the departure of its lead AI policy architect reveals a structural tension at the center of US AI governance: the White House is moving toward its most interventionist posture in frontier AI markets at the precise moment when the internal expertise needed to execute that intervention responsibly is walking out the door. The mechanism being proposed — equity ownership tied to a public wealth fund — is not inherently incoherent, but it requires governance architecture that does not yet publicly exist, and the exit of Krishnan removes the official most likely to have been building it.

Sources

1. TechCrunch – Sriram Krishnan is leaving his role as White House AI advisor
2. TechCrunch – The Trump administration might take an equity stake in OpenAI
3. STAT+ – Detailed data show Pfizer’s monthly obesity drug continues to show potential

AI-generated editorial illustration · TemperatureZero · June 7, 2026